Cabazitaxel: A Guide to Its Use in Hormone-Refractory Metastatic Prostate Cancer-Reference-Cited by-同舟云学术

Cabazitaxel: A Guide to Its Use in Hormone-Refractory Metastatic Prostate Cancer

Published:2013-03-27 Issue:5 Volume:30 Page:359-365
ISSN:1170-229X
Container-title:Drugs & Aging
language:en
Short-container-title:Drugs Aging

Author:

Keating Gillian M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Geriatrics and Gerontology

Link

http://link.springer.com/content/pdf/10.1007/s40266-013-0078-8.pdf

Reference29 articles.

1. National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN guideline): prostate cancer (version 3.2012). Fort Washington: National Comprehensive Cancer Network; 2012.

2. Oudard S. TROPIC: phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol. 2011;7(4):497–506.

3. Sartor AO. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol. 2011;4:18.

4. Villanueva C, Bazan F, Kim S, et al. Cabazitaxel: a novel microtubule inhibitor. Drugs. 2011;71(10):1251–8.

5. Tsao CK, Seng S, Oh WK, et al. Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. Clin Med Insights Oncol. 2011;5:163–9.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platelet count and dose, but not comorbidities, predict severe neutropenia in cabazitaxel-treated prostate cancer patients: A retrospective observational study;Int. Journal of Clinical Pharmacology and Therapeutics;2023-09-01

2. Herbal Drugs to Targets in the Treatment of Cancer - A Futuristic Approach;Current Cancer Therapy Reviews;2023-08

3. Medicinal plants and bioactive natural compounds for cancer treatment: Important advances for drug discovery;Phytochemistry Letters;2019-06

4. New horizons in the management of castrate-resistant prostate cancer;Journal of Clinical Urology;2017-09-13

5. Pharmaceuticals that contain polycyclic hydrocarbon scaffolds;Chemical Society Reviews;2015